G-Protein Coupled
Receptors
• G proteins, also known as guanine nucleotide-binding
proteins, involved in transmitting signals and function
as molecular switches.
• G protein-coupled receptors (GPCRs), also known
as seven-transmembrane domain receptors, 7T
receptors, serpentine receptor, and G protein-linked
receptors (GPLR),
• It constitute a large protein family of receptors that
sense molecules outside the cell and activate
inside signal transduction pathways and ultimately,
cellular responses.
• They are called seven-transmembrane receptors
because they pass through the cell membrane seven
times.
• Humans express over 800 GPCRs that make up the
third largest family of genes in humans.
• GPCRs are the targets for many drugs; perhaps half
of all non-antibiotic prescription drugs act at these
receptors.
Structure of G Protein
 The structure of a GPCR can be divided into three
parts:
1.The extra-cellular region, consisting of the N terminus
and three extracellular loops (ECL1–ECL3);
2. The TM region, consisting of seven a-helices(TM1–
TM7)
3. The intracellular region, consisting of three intra-
cellular loops (ICL1–ICL3), an intracellular
amphipathic helix (H8), and the C terminus .
G protein complexes are Made up
• 23 alpha (α)
• 7 beta (β)
• 12 gamma (γ) subunits.
• Beta and gamma subunits can form a stable dimeric
complex referred to as the beta-gamma complex
• In a broad sense, the extracellular region modulates
ligand access; the TM region forms the structural core,
binds ligands and transduces this information to the
intracellular region through conformational changes, and
the intracellular region interfaces with cytosolic signalling
proteins
• The α subunits fall into four families (Gs, Gi, Gq, and
G12/13) which are responsible for coupling GPCRs to
relatively distinct effectors.
• GPCRs are responsible for every aspect of human biology
from vision, taste, sense of smell, sympathetic and
parasympathetic nervous functions, metabolism, and immune
regulation to reproduction.
• ~45% of all pharmaceutical drugs are known to target GPCRs
• Robert Lefkowitz and Brian Kobilka: the 2012 Nobel Prize in
Chemistry for groundbreaking discoveries that reveal the inner
workings of an important family of receptors: G-protein–
coupled receptors
GPCR: Classification
Signal molecules/ Ligands of GPCRs
• GPCRs interact with a number of ligands ranging from
photons, ions, amino acids, odorants, pheromones,
eicosanoids, neurotransmitters, peptides, proteins, and
hormones.
• Nevertheless, for the majority of GPCRs, the identity
of their natural ligands is still unknown, hence remain
orphan receptors
Signal molecules
• Biogenic amines: Adrenaline, noradrenaline, dopamine, 5-HT,
histamine, acetylcholine
• Amino acids and ions: Glutamate, Ca2+, GABA
• Lipids : PAF, prostaglandins, leukotrienes,
• Peptides / proteins : GnRH, angiotensin, bradykinin,
thrombin, bombesin, glucagon, calcitonin, vasoactive intestinal
peptides, PTH, FSH, LH, TSH
• Nucleotides : adenine nucleotides, uridine nucleotides
Others : Light, odorants, pheromones, opiates
Physiological roles
• Visual sense: Rhodopsin
• Sense of smell: Olfactory receptor
• Behavioral and mood regulation: Serotonin, dopamine,
GABA and glutamate
• Immune system activity and inflammation: Chemokine
receptors, histamine receptors
• ANS transmission: β adrenergic receptors
• Apoptosis
GPC Receptors
MECHANISM
• When an agonist binds to a GPCR, there is a
conformational change in the receptor that is
transmitted from the ligand-binding pocket to the
second and third intracellular loops of the receptor
which couple to the G protein heterotrimer.
• GPCR results in a conformation change in the
receptor that is transmitted to the bound Gα subunit .
• This conformational change causes the α subunit to
exchange its bound GDP for GTP.
• Binding of GTP activates the α subunit and causes it to
release both the βγ dimer and the receptor, and active
signaling molecules, both the GTP-bound α subunit and
the βγ heterodimer become and active signaling molecules
• The interaction of the agonist-bound GPCR with the G
protein is transient; following activation of one G protein,
the receptor is freed to interact with other G proteins.
• There are two principal signal transduction pathways involving
the G protein–coupled receptors:
• the cAMP signal pathway and
• the phosphatidylinositol signal pathway
• Depending on the nature of the subunit, the active, GTP-bound
form binds to and regulates effectors such as adenylyl cyclase
(via Gs ) or phospholipase C (via Gq ).
• The subunit can regulate many effectors including ion
channels and enzymes such as PI3-K(phosphoinositide 3-
kinase).
• The G protein remains active until the GTP bound to the
subunit is hydrolyzed to GDP.
• The α subunit has a slow intrinsic rate of GTP hydrolysis that
is modulated by a family of proteins termed regulators of G
protein signaling (RGSs).
• The RGS proteins greatly accelerate the hydrolysis of GTP and are
potentially attractive drug targets.
• Once the GDP bound to the α subunit is hydrolyzed to GDP, the βγ
subunit and receptor recombine to form the inactive receptor-G
protein heterotrimer basal complex that can be reactivated by
another ligand-binding event
• The main targets for G-proteins, through which GPCRs
control different aspects of cell function are
• adenylyl cyclase, the enzyme responsible for cAMP
formation
• phospholipase C, the enzyme responsible for inositol
phosphate and diacylglycerol (DAG) formation
• ion channels, particularly calcium and potassium channels
• Rho A/Rho kinase, a system that controls the activity of
many signalling pathways controlling cell growth and
proliferation, smooth muscle contraction, etc.
The Adenylyl cyclase/cAMP system
• cAMP is a nucleotide
• Synthesized within the cell from ATP by membrane-bound,
adenylyl cyclase
• Produced continuously
• Inactivated by hydrolysis to 5´-AMP, by the
Phosphodiesterases
• Common mechanism, namely the activation of protein kinases
• Involved in:
Energy metabolism
Cell division and cell differentiation
Ion transport, ion channels
Contractile proteins in smooth muscle
Nucleotide Exchange Factors (Gefs)
• Integrate extracellular signals from membrane receptors to
produce cytoskeletal changes
• this pathway provides an additional effector system for cAMP
signaling and drug action that can act independently or
cooperatively with PKA
• Activation of diverse signaling pathways, regulate :
Phagocytosis
Progression through the cell cycle
Cell adhesion
Gene expression
Apoptosis
Phosphodiesterases
• Hydrolyze the cyclic 3',5'-phosphodiester bond in cAMP
and cGMP
• >50 different PDE proteins which are divided into 11
subfamilies
• Drug targets for :
Asthma
Cardiovascular diseases such as heart failure
Atherosclerotic coronary and peripheral arterial
disease
Neurological disorders
The Phospholipase C/ inositol phosphate
system
• 1950s by Hokin and Hokin
• PIP2 is the substrate for a membrane-bound enzyme,
phospholipase Cβ (PLCβ),
• Which splits it into DAG and inositol (1,4,5)
trisphosphate (IP3)
• Both function as second messengers
• IP3 receptor- a ligand-gated calcium channel present
on the membrane of the endoplasmic reticulum
Diacylglycerol and protein kinase C
• DAG, unlike the inositol phosphates, is highly lipophilic and
remains within the membrane
• Binds to a specific site on the PKC molecule, which migrates from
the cytosol to the cell membrane in the presence of DAG, thereby
becoming activated
• 10 different mammalian PKC subtypes
• Kinases in general play a central role in signal transduction, and
control many different aspects of cell function
The Rho/Rho kinase system
• Activated by certain GPCRs (and also by non-GPCR mechanisms),
which couple to G-proteins of the G12/13 type
• Rho-GDP, the resting form, is inactive
• When GDP-GTP exchange occurs, Rho is activated
• In turn activates Rho kinase
• Smooth muscle contraction and proliferation, angiogenesis and
synaptic remodeling
• Important in the pathogenesis of pulmonary hypertension
Conclusion
• Nearly 40% of the drugs approved for marketing by the
FDA target GPCRs
• 800-1,000 different GPCRs and the drugs that are
marketed target less than 50 GPCRs
• GPCR will continue to be highly important in clinical
medicine because of their large number, wide expression
and role in physiologically important responses
• Future discoveries will reveal new GPCR drugs, in part
because it is relatively easy to screen for pharmacologic
agents that access these receptors and stimulate or block
receptor-mediated biochemical or physiological
responses
G protein coupled receptor

G protein coupled receptor

  • 1.
  • 2.
    • G proteins,also known as guanine nucleotide-binding proteins, involved in transmitting signals and function as molecular switches. • G protein-coupled receptors (GPCRs), also known as seven-transmembrane domain receptors, 7T receptors, serpentine receptor, and G protein-linked receptors (GPLR), • It constitute a large protein family of receptors that sense molecules outside the cell and activate inside signal transduction pathways and ultimately, cellular responses.
  • 3.
    • They arecalled seven-transmembrane receptors because they pass through the cell membrane seven times. • Humans express over 800 GPCRs that make up the third largest family of genes in humans. • GPCRs are the targets for many drugs; perhaps half of all non-antibiotic prescription drugs act at these receptors.
  • 4.
    Structure of GProtein  The structure of a GPCR can be divided into three parts: 1.The extra-cellular region, consisting of the N terminus and three extracellular loops (ECL1–ECL3); 2. The TM region, consisting of seven a-helices(TM1– TM7) 3. The intracellular region, consisting of three intra- cellular loops (ICL1–ICL3), an intracellular amphipathic helix (H8), and the C terminus .
  • 6.
    G protein complexesare Made up • 23 alpha (α) • 7 beta (β) • 12 gamma (γ) subunits. • Beta and gamma subunits can form a stable dimeric complex referred to as the beta-gamma complex • In a broad sense, the extracellular region modulates ligand access; the TM region forms the structural core, binds ligands and transduces this information to the intracellular region through conformational changes, and the intracellular region interfaces with cytosolic signalling proteins • The α subunits fall into four families (Gs, Gi, Gq, and G12/13) which are responsible for coupling GPCRs to relatively distinct effectors.
  • 8.
    • GPCRs areresponsible for every aspect of human biology from vision, taste, sense of smell, sympathetic and parasympathetic nervous functions, metabolism, and immune regulation to reproduction. • ~45% of all pharmaceutical drugs are known to target GPCRs
  • 9.
    • Robert Lefkowitzand Brian Kobilka: the 2012 Nobel Prize in Chemistry for groundbreaking discoveries that reveal the inner workings of an important family of receptors: G-protein– coupled receptors
  • 10.
  • 12.
    Signal molecules/ Ligandsof GPCRs • GPCRs interact with a number of ligands ranging from photons, ions, amino acids, odorants, pheromones, eicosanoids, neurotransmitters, peptides, proteins, and hormones. • Nevertheless, for the majority of GPCRs, the identity of their natural ligands is still unknown, hence remain orphan receptors
  • 13.
    Signal molecules • Biogenicamines: Adrenaline, noradrenaline, dopamine, 5-HT, histamine, acetylcholine • Amino acids and ions: Glutamate, Ca2+, GABA • Lipids : PAF, prostaglandins, leukotrienes, • Peptides / proteins : GnRH, angiotensin, bradykinin, thrombin, bombesin, glucagon, calcitonin, vasoactive intestinal peptides, PTH, FSH, LH, TSH
  • 14.
    • Nucleotides :adenine nucleotides, uridine nucleotides Others : Light, odorants, pheromones, opiates
  • 15.
    Physiological roles • Visualsense: Rhodopsin • Sense of smell: Olfactory receptor • Behavioral and mood regulation: Serotonin, dopamine, GABA and glutamate • Immune system activity and inflammation: Chemokine receptors, histamine receptors • ANS transmission: β adrenergic receptors • Apoptosis
  • 16.
  • 17.
  • 18.
    • When anagonist binds to a GPCR, there is a conformational change in the receptor that is transmitted from the ligand-binding pocket to the second and third intracellular loops of the receptor which couple to the G protein heterotrimer. • GPCR results in a conformation change in the receptor that is transmitted to the bound Gα subunit . • This conformational change causes the α subunit to exchange its bound GDP for GTP.
  • 19.
    • Binding ofGTP activates the α subunit and causes it to release both the βγ dimer and the receptor, and active signaling molecules, both the GTP-bound α subunit and the βγ heterodimer become and active signaling molecules • The interaction of the agonist-bound GPCR with the G protein is transient; following activation of one G protein, the receptor is freed to interact with other G proteins.
  • 21.
    • There aretwo principal signal transduction pathways involving the G protein–coupled receptors: • the cAMP signal pathway and • the phosphatidylinositol signal pathway
  • 22.
    • Depending onthe nature of the subunit, the active, GTP-bound form binds to and regulates effectors such as adenylyl cyclase (via Gs ) or phospholipase C (via Gq ). • The subunit can regulate many effectors including ion channels and enzymes such as PI3-K(phosphoinositide 3- kinase). • The G protein remains active until the GTP bound to the subunit is hydrolyzed to GDP. • The α subunit has a slow intrinsic rate of GTP hydrolysis that is modulated by a family of proteins termed regulators of G protein signaling (RGSs).
  • 23.
    • The RGSproteins greatly accelerate the hydrolysis of GTP and are potentially attractive drug targets. • Once the GDP bound to the α subunit is hydrolyzed to GDP, the βγ subunit and receptor recombine to form the inactive receptor-G protein heterotrimer basal complex that can be reactivated by another ligand-binding event
  • 24.
    • The maintargets for G-proteins, through which GPCRs control different aspects of cell function are • adenylyl cyclase, the enzyme responsible for cAMP formation • phospholipase C, the enzyme responsible for inositol phosphate and diacylglycerol (DAG) formation • ion channels, particularly calcium and potassium channels • Rho A/Rho kinase, a system that controls the activity of many signalling pathways controlling cell growth and proliferation, smooth muscle contraction, etc.
  • 25.
    The Adenylyl cyclase/cAMPsystem • cAMP is a nucleotide • Synthesized within the cell from ATP by membrane-bound, adenylyl cyclase • Produced continuously • Inactivated by hydrolysis to 5´-AMP, by the Phosphodiesterases • Common mechanism, namely the activation of protein kinases • Involved in: Energy metabolism Cell division and cell differentiation Ion transport, ion channels Contractile proteins in smooth muscle
  • 29.
    Nucleotide Exchange Factors(Gefs) • Integrate extracellular signals from membrane receptors to produce cytoskeletal changes • this pathway provides an additional effector system for cAMP signaling and drug action that can act independently or cooperatively with PKA • Activation of diverse signaling pathways, regulate : Phagocytosis Progression through the cell cycle Cell adhesion Gene expression Apoptosis
  • 31.
    Phosphodiesterases • Hydrolyze thecyclic 3',5'-phosphodiester bond in cAMP and cGMP • >50 different PDE proteins which are divided into 11 subfamilies • Drug targets for : Asthma Cardiovascular diseases such as heart failure Atherosclerotic coronary and peripheral arterial disease Neurological disorders
  • 32.
    The Phospholipase C/inositol phosphate system • 1950s by Hokin and Hokin • PIP2 is the substrate for a membrane-bound enzyme, phospholipase Cβ (PLCβ), • Which splits it into DAG and inositol (1,4,5) trisphosphate (IP3) • Both function as second messengers • IP3 receptor- a ligand-gated calcium channel present on the membrane of the endoplasmic reticulum
  • 34.
    Diacylglycerol and proteinkinase C • DAG, unlike the inositol phosphates, is highly lipophilic and remains within the membrane • Binds to a specific site on the PKC molecule, which migrates from the cytosol to the cell membrane in the presence of DAG, thereby becoming activated • 10 different mammalian PKC subtypes • Kinases in general play a central role in signal transduction, and control many different aspects of cell function
  • 37.
    The Rho/Rho kinasesystem • Activated by certain GPCRs (and also by non-GPCR mechanisms), which couple to G-proteins of the G12/13 type • Rho-GDP, the resting form, is inactive • When GDP-GTP exchange occurs, Rho is activated • In turn activates Rho kinase • Smooth muscle contraction and proliferation, angiogenesis and synaptic remodeling • Important in the pathogenesis of pulmonary hypertension
  • 38.
    Conclusion • Nearly 40%of the drugs approved for marketing by the FDA target GPCRs • 800-1,000 different GPCRs and the drugs that are marketed target less than 50 GPCRs • GPCR will continue to be highly important in clinical medicine because of their large number, wide expression and role in physiologically important responses • Future discoveries will reveal new GPCR drugs, in part because it is relatively easy to screen for pharmacologic agents that access these receptors and stimulate or block receptor-mediated biochemical or physiological responses